maulana muharam(1*), Dewi Wahyu Firina(2), Dessy Mizarti(3)

(1) Pulmonology and Respirology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang, West Sumatera, Indonesia
(2) Pulmonology and Respirology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang, West Sumatera, Indonesia
(3) Pulmonology and Respirology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang, West Sumatera, Indonesia
(*) Corresponding Author



Tuberculosis can develop to multi drug resistant tuberculosis, this will be a serious health problem, not only in Indonesia, also in the world. This disease complexity, length of treatment, adverse effect of drug, make it management become challenging. Pregnancy with physiological changes in it made pregnant woman susceptible to infection, include tuberculosis infection. Data about MDR TB in pregnancy were not much, because TB screening in pregnancy were not often done, also pregnancy it self almost exclude from any trial. Because of MDR TB regiment adverse effect, much of clinician suggest woman in MDR TB treatment to not get pregnant while on it. Management MDR TB on pregnancy use individual regiment, by keep secure and safety aspect of patient, also her fetus.


tuberculosis, multi drug resistant tuberculosis, pregnancy

Full Text:



Baddeley A, Bartens M-C, Dean A, Dias HM, Falzon D, Floyd K, et al. Global Tuberculosis Report 2020. 2020th ed. Kasaeva T, editor. Geneva: World Health Organization; 2020. 6–157 p.

Pambudi I, Lukitosari E, Kusuma Dewi R, Permata Y, Sinaga BY, Wulandari DA, et al. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2020. 1–55 p.

Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, et al. Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis. 2021;72(7):1158–68.

Alene KA, Jegnie A, Adane AA. Multidrug- resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. BJOG An Int J Obstet Gynaecol. 2020;82:16–36.

Lukitosari E, Dewi RK, Permata Y. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat Di Indonesia. 2020th ed. Lukitosari E, Dewi RK, Permata Y, editors. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020. 1–72 p.

K.J. S, A. B, G.K. H, S.M. G. Tuberculosis in pregnant women and neonates: A meta- review of current evidence. Paediatr Respir Rev. 2020;36:27–32.

Raznatovska OM, Shalmin OS. Features of pregnancy course in women with chemoresistant tuberculosis (a literature review). Zaporozhye Med J. 2019;21(5):691– 6.

Green KD, Garneau-Tsodikova S. Resistance in tuberculosis: What do we know and where can we go? Front Microbiol. 2013;4(JUL):1–7.

Sri MM, Nawas A, Soetoyo DK. Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. J Respirologi Indones. 2010;30(2):92–104.

Indonesia KKR. Surat Edaran Nomor HK.02.02/III.1/936/2021 tentang Perubahan Alur Diagnosis dan Pengobatan Tuberkulosis di Indonesia. Jakarta; 2021.

Benson RC, Pernoll ML. Handbook of Obstetry and Gynecology. 9th ed. Pernoll ML, editor. The McGraw-Hill Education Asia. Jakarta: The McGraw-Hill Companies, Inc; 2009. 34–56 p.

Seung KJ, Keshavjee S, Rich ML. Multidrug- resistant and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med2015;5(1TB):1–20.

Shin S, Guerra D, Rich M, Seung KJ, Mukherjee J, Joseph K, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: A report of 7 cases. Clin Infect Dis. 2003;36(8):996–1003.

Palacios E, Dallman R, Muñoz M, Hurtado R, Chalco K, Guerra D, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in lima, peru. Clin Infect Dis. 2009;48(10):1413–9.

Drobac PC, Del Castillo H, Sweetland A, Anca G, Joseph JK, Furin J, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: Long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis. 2005;40(11):1689–92.

Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol. 2020;135(6):1444–53.

Bar-Oz B, Moretti ME, Boskovic R, O’Brien L, Koren G. The safety of quinolones-A meta- analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143(2):75–8.

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2019;200(10):e93-e142

Snow K, Bekker A, Huang G, Graham S. Tuberculosis in pregnant women and neonates: A meta-review of current evidence. Paediatric Respiratory Reviews. 2020.

Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. Journal of thoracic disease. 2018;10(5):3102.

Alene KA, Adane AA, Jegnie A. Impact of multidrug-resistant tuberculosis and its medications on adverse maternal and perinatal outcomes: protocol for a systematic review and meta- analysis. BMJ open. 2019;9(12).

Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS medicine. 2019;16(8).


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address for Correspondence:

Editorial Room Andalas Obstetrics and Gynecology Journal 3rd floor of KSM Obstetrics and Gynecology
RSUP Dr. M. Djamil Padang, Jl. Perintis Kemerdekaan Padang, Sumatara Barat, 25127